Asian Journal of Andrology

ORIGINAL ARTICLE
Year
: 2014  |  Volume : 16  |  Issue : 3  |  Page : 472--477

Avanafil for male erectile dysfunction: a systematic review and meta-analysis


Yuan-Shan Cui, Nan Li, Huan-Tao Zong, Hui-Lei Yan, Yong Zhang 
 Department of Urology, Beijing Tian-Tan Hospital, Capital Medical University, Beijing, China

Correspondence Address:
Yong Zhang
Department of Urology, Beijing Tian-Tan Hospital, Capital Medical University, Beijing
China

Avanafil, a potent new selective phosphodiesterase type 5 (PDE5) inhibitor, has been developed for the treatment of erectile dysfunction (ED). We carried out a systematic review and meta-analysis to assess the efficacy and safety of this drug for the treatment of ED. A literature review was performed to identify all published randomized, double-blind, placebo-controlled trials of avanafil for the treatment of ED. The search included the following databases: MEDLINE, EMBASE and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated. Four publications, involving a total of 1381 patients, were used in the analysis, including four randomized controlled trials (RCTs) that compared avanafil with a placebo. Among the co-primary efficacy end points indicating that avanafil 100 mg was more effective than a placebo were successful vaginal penetration (SEP2) (the odds ratio (OR) =5.06, 95% confidence interval (CI) =3.29-7.78, P< 0.00001) and successful intercourse (SEP3) (OR = 3.99, 95% CI = 2.80-5.67, P< 0.00001). Men randomized to receive avanafil were less likely than those receiving the placebo to drop out due to an adverse event (AE) (OR = 1.48, 95% CI = 0.54-4.08, P= 0.44). Specific AEs with avanafil included headache and flushing, which were significantly less likely to occur with placebo. This meta-analysis indicates that avanafil 100 or 200 mg is an effective and well-tolerated treatment for ED. Compared with avanafil 100 mg, patients who take avanafil 200 mg are more likely to experience headaches.


How to cite this article:
Cui YS, Li N, Zong HT, Yan HL, Zhang Y. Avanafil for male erectile dysfunction: a systematic review and meta-analysis.Asian J Androl 2014;16:472-477


How to cite this URL:
Cui YS, Li N, Zong HT, Yan HL, Zhang Y. Avanafil for male erectile dysfunction: a systematic review and meta-analysis. Asian J Androl [serial online] 2014 [cited 2021 Sep 28 ];16:472-477
Available from: https://www.ajandrology.com/article.asp?issn=1008-682X;year=2014;volume=16;issue=3;spage=472;epage=477;aulast=Cui;type=0